AML patients receive cancer drug DCP-001
December 3, 2018DCprime (spin-off VUmc) announces first patient dosed in phase 2 ADVANCE-II study with DCP-001 in patients with Acute Myeloid Leukemia. This administration marks the official start of the phase 2 study in the ADVANCE-II study. A total of 20 patients with acute myeloid leukemia (AML), a rare form of leukemia, participate in this study. A recently completed phase I study showed that the cancer drug DCP-001, a vaccine based on dendritic cells, is generally safe and capable of triggering an anti-cancer immune response in patients with AML.
Read here the full press release.
More news
NWO-Demonstrator Grant for methane leak detection
Imran Avci and Davide Iannuzzi (Vrije Univeriteit Amsterdam) have been awarded an NWO-Demonstrator Grant. The grant will give them the opportunity to test whether their PAS-WRAP technology can be used to detect methane leaks in oil and gas extraction facilities. The project is based on a new approach to gas trace detection that offers high […]
News
EU-rapport: HvA is voorbeeld in ondernemerschaps-onderwijs
Nederland loopt voorop in het integreren van ondernemerschap en innovatie in het hoger onderwijs ten opzichte van andere Europese landen. Dat blijkt uit een rapport dat in opdracht van de OESO tot stand kwam. De HvA wordt als voorbeeld genoemd voor andere instellingen. Supporting Entrepreneurship and Innovation in Higher Education in the Netherlands werd gepubliceerd […]
News
New start-up Fitsurance wants to improve sustainable employability and quality of life of employees
Fitsurance, the latest start-up from Demonstrator Lab, wants to improve the quality of life of employees. They focus on sustainable employability, increasing work productivity and general well-being of employees. They aim to reduce sick-leaves and absenteeism among the workforce of any employer. This implies a radical shift from the current thinking of a curative way […]
News